Teachers Advisors LLC lifted its stake in Bristol-Myers Squibb Co (NYSE:BMY) by 0.9% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,683,006 shares of the biopharmaceutical company’s stock after purchasing an additional 34,326 shares during the quarter. Teachers Advisors LLC’s holdings in Bristol-Myers Squibb were worth $228,641,000 as of its most recent SEC filing.
Several other institutional investors also recently made changes to their positions in BMY. Kentucky Retirement Systems acquired a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $7,225,000. Amussen Hunsaker Associates LLC increased its holdings in Bristol-Myers Squibb by 11,420.0% in the 3rd quarter. Amussen Hunsaker Associates LLC now owns 5,760 shares of the biopharmaceutical company’s stock worth $303,000 after buying an additional 5,710 shares during the period. High Falls Advisors Inc acquired a new position in Bristol-Myers Squibb in the 3rd quarter worth approximately $222,000. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp increased its holdings in Bristol-Myers Squibb by 976.9% in the 3rd quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 238,000 shares of the biopharmaceutical company’s stock worth $14,775,000 after buying an additional 215,900 shares during the period. Finally, Koshinski Asset Management Inc. increased its holdings in Bristol-Myers Squibb by 99.8% in the 3rd quarter. Koshinski Asset Management Inc. now owns 16,364 shares of the biopharmaceutical company’s stock worth $1,016,000 after buying an additional 8,175 shares during the period. 72.77% of the stock is owned by hedge funds and other institutional investors.
Several brokerages recently weighed in on BMY. ValuEngine upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a report on Friday, December 7th. Societe Generale set a $47.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Wednesday, November 14th. BMO Capital Markets raised their price objective on shares of Bristol-Myers Squibb from $55.00 to $58.00 and gave the stock a “market perform” rating in a research note on Friday, November 16th. Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 price objective on shares of Bristol-Myers Squibb in a research note on Thursday, December 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of Bristol-Myers Squibb in a research note on Tuesday, November 27th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average price target of $61.84.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 25th. The biopharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.18. Bristol-Myers Squibb had a net margin of 6.50% and a return on equity of 47.89%. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. As a group, analysts forecast that Bristol-Myers Squibb Co will post 3.87 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, February 1st. Stockholders of record on Friday, January 4th will be given a dividend of $0.41 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.40. The ex-dividend date is Thursday, January 3rd. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.17%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 53.16%.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic areas, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Further Reading: Catch-Up Contributions
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.